Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer

References

• Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664–672. doi:10.1002/cncr.2909825336398
   PubMed Web of Science ®Google Scholar
• Guohua H, Hongyang L, Zhiming J, Danhua Z, Haifang W. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs. Biosens Bioelectron. 2017;97:184–195. doi:10.1016/j.bios.2017.05.05028599178
   PubMed Web of Science ®Google Scholar
• Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol. 2014;41:133–142. doi:10.1053/j.seminoncol.2013.12.01524565587
   PubMed Web of Science ®Google Scholar
• Wang JP, Zhou XL, Yan JP, Zheng RQ, Wang W. Nanobubbles as ultrasound contrast agent for facilitating small cell lung cancer imaging. Oncotarget. 2017;8:78153–78162. doi:10.18632/oncotarget.1815529100457
   PubMedGoogle Scholar
• Huang Z, Xu D, Zhang F, Ying Y, Song L. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. Clin Transl Oncol. 2016;18:1019–1025. doi:10.1007/s12094-015-1479-426886220
   PubMed Web of Science ®Google Scholar
• Kiseli M, Caglar GS, Gursoy AY, et al. Pro-gastrin releasing peptide: a new serum marker for endometrioid adenocarcinoma. Gynecol Obstet Invest. 2018;83:540–545. doi:10.1159/00048885429898448
   PubMed Web of Science ®Google Scholar
• Gong Z, Lu R, Xie S, et al. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer. Biochem Biophys Res Commun. 2016;479:312–318. doi:10.1016/j.bbrc.2016.09.06627639644
   PubMed Web of Science ®Google Scholar
• Khanna C, Rosenberg M, Vail DM. A review of paclitaxel and novel formulations including those suitable for use in dogs. J Vet Intern Med. 2015;29:1006–1012. doi:10.1111/jvim.1259626179168
   PubMed Web of Science ®Google Scholar
• Hirsh V. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014;14:129–141. doi:10.1586/14737140.2014.88171924467217
   PubMed Web of Science ®Google Scholar
• Ma WW, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res. 2013;19:5572–5579. doi:10.1158/1078-0432.CCR-13-135623918602
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24:179–191. doi:10.3109/1061186X.2015.105104926061298
   PubMed Web of Science ®Google Scholar
• Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2015;12:177–191.25146439
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou X, Shi Y, et al. Study on biodistribution and radioimmunoimaging of (131)iodine-labeled monoclonal antibody D-D3 against progastrin-releasing peptide31–98 in tumor-bearing mouse. Cancer Biother Radiopharm. 2011;26:229–235. doi:10.1089/cbr.2010.085521510749
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res. 2008;14:7813–7821. doi:10.1158/1078-0432.CCR-08-067819047109
   PubMed Web of Science ®Google Scholar
• Shen Y, Pi Z, Yan F, et al. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts. Int J Nanomedicine. 2017;12:5613–5629. doi:10.2147/IJN.S13640128848341
   PubMed Web of Science ®Google Scholar
• Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12:3–20.26033233
   PubMedGoogle Scholar
• Neshastehriz A, Tabei M, Maleki S, Eynali S, Shakeri-Zadeh A. Photothermal therapy using folate conjugated gold nanoparticles enhances the effects of 6MV X-ray on mouth epidermal carcinoma cells. J Photochem Photobiol B. 2017;172:52–60. doi:10.1016/j.jphotobiol.2017.05.01228527427
   PubMed Web of Science ®Google Scholar
• Keshavarz M, Moloudi K, Paydar R, et al. Alginate hydrogel co-loaded with cisplatin and gold nanoparticles for computed tomography image-guided chemotherapy. J Biomater Appl. 2018;33:161–169. doi:10.1177/088532821878235529933708
   PubMed Web of Science ®Google Scholar
• Offerman SC, Kadirvel M, Abusara OH, et al. N-tert-Prenylation of the indole ring improves the cytotoxicity of a short antagonist G analogue against small cell lung cancer. Medchemcomm. 2017;8:551–558. doi:10.1039/c6md00691d30108771
   PubMed Web of Science ®Google Scholar
• Shi XN, Li H, Yao H, et al. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. Mol Med Rep. 2015;12:6501–6508. doi:10.3892/mmr.2015.431026398439
   PubMed Web of Science ®Google Scholar
• Jin YH, Yim H, Park JH, Lee SK. Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis. Biochem Biophys Res Commun. 2003;305:974–980.12767926
   PubMed Web of Science ®Google Scholar
• Chohan TA, Qian H, Pan Y, Chen JZ. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. Curr Med Chem. 2015;22:237–263.25386824
   PubMed Web of Science ®Google Scholar
• Xu L, Wang C, Wen Z, et al. Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell. Immunol Lett. 2010;127:93–99. doi:10.1016/j.imlet.2009.10.00219854217
   PubMed Web of Science ®Google Scholar
• Sun M, Jiang R, Wang G, et al. Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer. Int J Oncol. 2013;42:1376–1382. doi:10.3892/ijo.2013.181323404055
   PubMed Web of Science ®Google Scholar
• Rubin SM, Sage J. Defining a new vision for the retinoblastoma gene: report from the 3rd international Rb meeting. Cell Div. 2013;8:13. doi:10.1186/1747-1028-8-624257515
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Witkiewicz AK, Knudsen ES. The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle. 2015;14:3812–3819. doi:10.1080/15384101.2015.101092225714546
   PubMed Web of Science ®Google Scholar
• Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013;14:297–306. doi:10.1038/nrm356723594950
   PubMed Web of Science ®Google Scholar
• Meder L, Konig K, Ozretic L, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138:927–938. doi:10.1002/ijc.2983526340530
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. doi:10.1038/ncomms737725758528
   PubMed Web of Science ®Google Scholar
• Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15:Ra32–Ra40.19182722
   PubMed Web of Science ®Google Scholar
• Chien MH, Lin CW, Cheng CW, Wen YC, Yang SF. Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opin Ther Targets. 2013;17:203–216. doi:10.1517/14728222.2013.74001223252422
   PubMed Web of Science ®Google Scholar
• Ali-Labib R, Louka ML, Galal IH, Tarek M. Evaluation of matrix metalloproteinase-2 in lung cancer. Proteomics Clin Appl. 2014;8:251–257. doi:10.1002/prca.20130008624415566
   PubMed Web of Science ®Google Scholar
• Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845. doi:10.1155/2014/15084525013758
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516. doi:10.1080/0192623070132033717562483
   PubMed Web of Science ®Google Scholar
• Jaiswal PK, Goel A, Mittal RD. Survivin: A molecular biomarker in cancer. Indian J Med Res. 2015;141:389–397. doi:10.4103/0971-5916.15925026112839
   PubMed Web of Science ®Google Scholar
• Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches. BioDrugs. 2014;28:27–39. doi:10.1007/s40259-013-0058-x23955284
   PubMed Web of Science ®Google Scholar
• Correia C, Lee SH, Meng XW, et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853:1658–1671. doi:10.1016/j.bbamcr.2015.03.01225827952
   PubMed Web of Science ®Google Scholar
• Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 2013;17:61–75. doi:10.1517/14728222.2013.73300123173842
   PubMed Web of Science ®Google Scholar
• Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104. doi:10.1038/sj.cdd.440047610200555
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. Oncogene. 2012;31:2805–2808. doi:10.1038/onc.2011.45921963852
   PubMed Web of Science ®Google Scholar